Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020

News | Stents

Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

October 22, 2020

Videos | Stents Drug Eluting

VIDEO: Results of the OPTIMIZE IDE Trial for the Svelte Drug Eluting Stent

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

October 19, 2020

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

October 19, 2020

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect

Feature | Cath Lab

No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

October 18, 2020

Videos | Cath Lab

VIDEO: Pre-emptive Treatment of Vulnerable Plaques With Bioresorbable Stents

Gregg Stone, M.D., presents the results of the PROSPECT ABSORB Trial in a press conference at the 2020 ranscatheter ...

October 17, 2020

The Abbott Vascular Xience Sierra drug eluting stent (DES). The XIENCE 28 and XIENCE 90 studies presented at TCT 2020 showed the stent can be used safely with only one month of dual antiplatelet therapy (DAPT). #TCT #TCTconnect #TCT2020

News | Stents Drug Eluting

Shorter DAPT With Xience Stent is Noninferior to Standard DAPT

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

October 16, 2020

The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

News | Stents

Medtronic Resolute Onyx Drug Eluting Stent First to Receive One-Month DAPT Indication

October 1, 2020 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual ...

October 01, 2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

News | Stents

TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI

May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) ...

May 17, 2020

Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.

News | Stents

Biotronik's Orsiro Stent Continues Excellent Results After Three Years

February 24, 2020 — Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the ...

February 24, 2020

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | Saloni Walimbe

Innovations in Cardiovascular Disease Treatment and the Rising Demand for Stents

Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high ...

February 11, 2020

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019

Feature | Stents Peripheral | Dave Fornell, Editor

No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

November 06, 2019

Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA

News | Peripheral Artery Disease (PAD)

Positive Data for the Ranger Drug-coated Balloon and Eluvia Vascular Stent

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting ...

November 06, 2019

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

Feature | TCT | Dave Fornell, Editor

6 Hot Topics in Interventional Cardiology at TCT 2019

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual Transca ...

November 04, 2019

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: New PLATINUM Diversity Data Shows Early DAPT Cessation OK in Minorities With New Generation Stent

Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional ...

October 17, 2019

News | Stents Drug Eluting

Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure

October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at ...

October 11, 2019